Deva Holdings (DEVA.IS)

Executive Summary

Deva Holdings, established in 1958 and headquartered in Istanbul, is a leading Turkish pharmaceutical company specializing in generic drugs, active pharmaceutical ingredients (APIs), and consumer healthcare products. With a valuation of approximately $13 billion and a public listing on Borsa Istanbul (ticker: DEVA.IS), the company has built a strong domestic presence and expanding international footprint. Deva's portfolio includes over 10 commercial products, covering a range of therapeutic areas, and its manufacturing capabilities support both internal production and third-party supply. The company benefits from Turkey's growing pharmaceutical market and its strategic location bridging Europe and Asia, enabling cost-effective production and distribution. Deva's long history and established relationships with healthcare providers position it as a reliable partner in generic drug development, while its focus on API manufacturing adds vertical integration advantages. The company's ability to navigate regulatory environments and maintain consistent quality has underpinned its resilience and steady growth.

Upcoming Catalysts (preview)

• Q3 2026New Generic Product Launches in Key Therapeutic Areas70% success
• Q4 2026Expansion into European API Supply Agreements60% success
• H1 2027Potential FDA Approval for Select Generic Drugs50% success